Company Filing History:
Years Active: 2012
Title: Innovations of Peter Juergen Cnota: A Pioneer in Respiratory Treatments
Introduction: Peter Juergen Cnota is an esteemed inventor based in Bad Homburg, Germany. With a remarkable contribution to respiratory disease treatment, he holds a significant patent that has implications for the medical field. His work is supported by his association with Meda Pharma GmbH & Co. KG, a company dedicated to pharmaceutical innovations.
Latest Patents: Peter Juergen Cnota's patent focuses on a unique combination of anticholinergics and phosphodiesterase type 4 (PDE 4) inhibitors for the treatment of respiratory diseases. The invention pertains to the use of inhaled or oral PDE 4 inhibitors alongside inhaled anticholinergic bronchodilators, particularly Roflumilast or AWD-12-281 combined with R,R-glycopyrrolate. This combination is specifically designed for symptomatic or prophylactic treatment of conditions like chronic obstructive pulmonary disease (COPD) and asthma. Additionally, the invention details a formulation for local application via inhalation devices, such as the Novolizer®.
Career Highlights: Throughout his career, Cnota has demonstrated a keen ability to innovate in pharmaceutical science, particularly in developing treatments for respiratory conditions. His focus on leveraging existing medications in new combinations showcases his commitment to enhancing patient care and improving therapeutic options.
Collaborations: Cnota has collaborated with several respected professionals in the field, including Joachim Maus and Istvan Szelenyi. These partnerships have enriched his research and development efforts, contributing to the successful completion of his innovative projects.
Conclusion: Peter Juergen Cnota's innovative work in the field of respiratory disease treatment highlights his impact on medical science. His patent serves as a testament to his dedication as an inventor and reflects the continuous drive for advancements in healthcare. With a strong foundation in collaboration and research, he is likely to contribute further to the evolution of therapeutic solutions for patients with respiratory ailments.